While liver toxicity is a serious concern for fluoroquinolone antibiotics, researchers suspected the drugs might be able to actually treat another major cause of liver failure. Unfortunately, preliminary research has been disappointing.

Researchers from the University of Manitoba in Canada published a paper called “Use of Fluoroquinolones in Patients with Chronic Hepatitis C Virus-Induced Liver Failure” in the American Society for Microbiology’s Antimicrobial Agents and Chemotherapy, a peer-reviewed journal. The paper was published in 2002.

Fluoroquinolone antibiotics are a class of drugs used to treat bacterial infections. They are widely used since they are very effective. But concerns about liver toxicity have begun to add up in recent years. Despite this, the Canadian research team believed the drug may help treat hepatitis C, one of the major causes of liver failure.

Hepatitis C is a virus, not a bacterium. However, in a test tube, fluoroquinolone antibiotics appear to interfere with the virus’s replication, and the researchers wanted to see if that was also true in a person.

One of the main treatments for hepatitis C is a liver transplant, but for many patients, this just puts them back to square one in terms of their liver failure, as they still have hepatitis C in their blood. Reducing the amount of hepatitis C in a patient’s blood before a liver transplant can improve outcomes for hepatitis C patients. So, hypothetically, a fluoroquinolone antibiotic could help hepatitis C patients, especially right before a liver transplant.

Unfortunately, the researchers did not find that fluoroquinolone antibiotics were effective when tested at the human level. Many drugs are very effective in a test tube, but the complexities of the human body are a whole new environment, with many unforeseeable factors that could negate them. It appeared that doses of ciprofloxacin given to liver failure patients did not change the levels of hepatitis C in their blood.

More recently, a class action lawsuit investigation has been launched to explore the possibility of legal action over reports of fluoroquinolone liver failure. Allegedly, many patients taking fluoroquinolone antibiotics have suffered serious cases of liver toxicity and liver failure as an alleged reaction to various fluoroquinolone antibiotics.

Such a fluoroquinolone class action lawsuit could allege that drug makers were aware, or reasonably should have been aware, of the serious risks allegedly associated with fluoroquinolone antibiotics, and failed to do enough to protect the public from this alleged risk.